Incidence and impact of activating mutations of the RAS-RAF- MEK-ERK pathway in patients with philadelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative disorders-unclassified (MDS/MPD-U)

dc.contributorHosp Israelita Albert Einstein
dc.contributorHEMOMED
dc.contributorHosp Brigadeiro
dc.contributorCtr Hematol Sao Paulo
dc.contributorHosp Leforte
dc.contributorHosp Mario Covas
dc.contributorFundacao Hosp Amaral Carvalho
dc.contributorUniv Fed Rio Grande do Norte
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorClin Oncol Integrada
dc.contributorUniversidade Federal da Bahia (UFBA)
dc.contributorUniversidade Federal de Goiás (UFG)
dc.date.accessioned2015-11-03T18:24:51Z
dc.date.available2015-11-03T18:24:51Z
dc.date.created2015-11-03T18:24:51Z
dc.date.issued2014-12-06
dc.identifierBlood. Washington: Amer Soc Hematology, v. 124, n. 21, p. 1-4, 2014.
dc.identifier0006-4971
dc.identifierhttp://hdl.handle.net/11449/130344
dc.identifierWOS:000349243503205
dc.languageeng
dc.publisherAmer Soc Hematology
dc.relationBlood
dc.relation15.132
dc.relation6,434
dc.rightsAcesso aberto
dc.sourceWeb of Science
dc.titleIncidence and impact of activating mutations of the RAS-RAF- MEK-ERK pathway in patients with philadelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative disorders-unclassified (MDS/MPD-U)
dc.typeOtros


Este ítem pertenece a la siguiente institución